Loading financials from SEC filings…
Drug manufacturers · Healthcare · Fiscal year ends Dec 31
Amylyx Pharmaceuticals reported revenue of $0 in the fiscal year ended Dec 2025, down 100.0% from the year before. Net income was −$145M. Operating cash flow of −$123M less capital expenditure of $138,000 left free cash flow of −$123M.
Ranks among the 78 drug manufacturers companies we cover (1st = best; for debt, the least indebted). Green = top third, red = bottom third.
Last 5 fiscal years
| Fiscal year | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0.3 | 22.2 | 381 | 87.4 | 0.0 |
| Cost of revenue | – | 3.0 | 25.4 | 6.0 | 0.0 |
| Gross profit | – | 19.2 | 355 | 81.4 | 0.0 |
| Research & development | 44.0 | 93.5 | 128 | 104 | 90.4 |
| Selling, general & admin | 38.9 | 127 | 188 | 114 | 62.9 |
| Operating income | −82.7 | −201 | 38.8 | −315 | −153 |
| Pre-tax income | −87.9 | −198 | 54.3 | −302 | −145 |
| Income tax | – | 0.8 | 5.0 | −0.4 | 0.0 |
| Net income | −87.9 | −198 | 49.3 | −302 | −145 |
| Diluted EPS | −13.35 | −3.39 | 0.70 | −4.43 | −1.53 |
| Diluted shares | 6.6 | 58.5 | 70.0 | 68.1 | 94.6 |
| Fiscal year | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Cash & equivalents | 50.2 | 62.5 | 170 | 77.4 | 227 |
| Receivables | – | 15.3 | 40.1 | 0.4 | 0.1 |
| Inventory | – | 9.8 | 38.3 | – | – |
| Current assets | 105 | 382 | 465 | 189 | 324 |
| Net PP&E | 0.5 | 2.6 | 2.7 | 1.0 | 0.3 |
| Total assets | 106 | 391 | 517 | 194 | 333 |
| Payables | 4.4 | 6.3 | 22.1 | 2.9 | 3.5 |
| Current liabilities | 17.4 | 46.6 | 82.0 | 28.4 | 22.7 |
| Total liabilities | 17.4 | 50.8 | 84.0 | 28.9 | 27.4 |
| Shareholders' equity | −151 | 341 | 433 | 165 | 305 |
| Fiscal year | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating cash flow | −74.8 | −180 | 11.9 | −168 | −123 |
| Capital expenditure | 0.4 | 2.5 | 1.2 | 0.2 | 0.1 |
| Free cash flow | −75.2 | −182 | 10.7 | −168 | −123 |
| Depreciation & amortisation | 0.1 | 0.5 | 1.1 | 0.9 | 0.5 |
| Stock-based compensation | 3.1 | 21.7 | 37.2 | 33.0 | 27.6 |
| Fiscal year | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue growth (YoY) | – | 7700.0% | 1612.9% | −77.1% | −100.0% |
| Operating income growth (YoY) | – | – | – | −911.1% | – |
| EPS growth (YoY) | – | – | – | −732.9% | – |
| Gross margin | – | 86.5% | 93.3% | 93.2% | – |
| Operating margin | −29013.3% | −905.7% | 10.2% | −360.2% | – |
| Net margin | −30853.0% | −892.4% | 12.9% | −345.4% | – |
| Return on equityBlank when equity is negative | – | −58.2% | 11.4% | −183.1% | −47.4% |
| ROCEEBIT ÷ (assets − current liabilities) | −93.7% | −58.4% | 8.9% | −190.5% | −49.5% |
| Free cash flow margin | −26369.1% | −820.5% | 2.8% | −192.1% | – |
| Cash conversion (CFO ÷ net income) | 0.85x | 0.91x | 0.24x | 0.56x | 0.85x |
| Receivable days | – | 251 | 38 | 2 | – |
| Inventory days | – | 1191 | 550 | – | – |
| Payable days | – | 763 | 317 | 180 | – |
| Current ratio | 6.03x | 8.20x | 5.66x | 6.67x | 14.3x |
Standardised figures from the company's XBRL filings with the SEC (10-K, 10-Q). Line items follow US GAAP tags, so a company's own statement layout may differ and some lines show “–” where the company does not report that item. Ratios are calculated from these figures. For education only; not investment advice or a recommendation.